Advertisement

Idiopathic Pulmonary Fibrosis

  • M. Del Donno
  • A. Di Sorbo
  • A. Micco
Chapter

Abstract

Chronic interstitial lung disease (ILD) is considered a heterogeneous group of pulmonary diseases usually classified on the basis of clinical, radiological and histological aspects, characterized by a variable degree of inflammation and fibrosis. The most diagnosed ILD are idiopathic pulmonary fibrosis (IPF), characterized by the presence of serious changes in the normal architecture of the pulmonary parenchyma, resulting in a progressive and often rapid respiratory functional decline. Although considered a rare disease, the IPF has seen a considerable increase in prevalence and mortality, over the last 10 years. Moreover, it has a worse outcome than most malignant tumours resulting in an average. IPF should be considered in all adult patients with unexplained chronic exertional dyspnoea, and commonly presents with cough, bibasilar inspiratory crackles and finger clubbing. The diagnosis of IPF requires exclusion of other known causes of interstitial lung disease (ILD) and the presence of a usual interstitial pneumoniae (UIP) pattern on high-resolution computed tomography (HRCT) in patients not subjected to surgical lung biopsy. The functional respiratory pattern is characterized by restrictive type of ventilatory compromise, reduction of the DLCO diffusion capacity, hypoxaemia during exercise and, then, at rest too. Despite the efforts made in scientific research and the therapeutic progress achieved, there are currently no drugs capable of achieving the remission and healing of this pathology. To date, there are only two drugs, pirfenidone and nintedanib, although not usable by all patients, able to drastically reduce symptoms and exacerbations, significantly improve the quality of life and, above all, stop the decline in respiratory function.

References

  1. 1.
    Raghu G, Collard HR, et al. An Official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Crystal RG, Bittermann PB. Interstitial lung diseases of unknown causes. N Engl J Med. 1984;31:154–61.CrossRefGoogle Scholar
  3. 3.
    Liebow AA. Definition and classification of interstitial pneumonias in human pathology. Prog Respir Res. 1975;8:1–31.CrossRefGoogle Scholar
  4. 4.
    Idiopathic pulmonary fibrosis: diagnosis and treatment. International Consensus Statement. Am J Respir Crit Care Med. 2000;161:646–64.Google Scholar
  5. 5.
    Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157:1301–15.PubMedCrossRefGoogle Scholar
  6. 6.
    Schwarz MI, King TE Jr. Interstitial lung disease. 2nd ed. Philadelphia: Mosby-Year Book; 1993. p. 60.Google Scholar
  7. 7.
    Thurlbeck WM, Miller RR, et al. Diffuse disease of the lung. A team approach. Philadelphia: BC Decker; 1991.Google Scholar
  8. 8.
    Liebow AA, Carrington CB. The interstitial pneumonias. In: Simon M, Potchen EJ, LeMay M, editors. Frontiers of pulmonary radiology. 1st ed. New York: Grune & Stratton; 1969. p. 102–41.Google Scholar
  9. 9.
    Katzenstein A-LA. Katzenstein and Askin’s surgical pathology of nonneoplastic lung disease. Philadelphia: W.B. Saunders; 1997.Google Scholar
  10. 10.
    Müller NL, Colby TV. Idiopathic interstitial pneumonias: high-resolution CT and histologic findings. Radiographics. 1997;17(4):1016–22.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Coultas DB, Zumwalt RE, et al. The epidemiology of interstitial lung disease. Am J Respir Crit Care Med. 1994;150:967–72.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Gunther A, Korfei M, Mahavadi P, et al. Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev. 2012;21:152–60.PubMedCrossRefPubMedCentralGoogle Scholar
  13. 13.
    Chilosi M, Carloni A, Rossi A, Poletti V. Premature lung aging and cellular senescence in the pathogenesis of idiopathic pulmonary fibrosis and COPD/emphysema. Transl Res. 2013;162:156–73.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Torres-Gonzalez E, et al. Role of endoplasmic reticulum stress in age-related susceptibility to lung fibrosis. Am J Respir Cell Mol Biol. 2012;46:748–56.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Gibson GJ, Loddenkemper R, Sibilie Y, Lundback B. The European Lung White Book. ERS. 2013.Google Scholar
  16. 16.
    Gribbin J, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61:980–5.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:810–6.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Agabiti N, Porretta MA, et al. Idiopathic Pulmonary Fibrosis (IPF) incidence and prevalence in Italy. Sarcoidosis Vasc Diffuse Lung Dis. 2014;31:180–6.Google Scholar
  19. 19.
    Harari S, Madotto F, Caminati A, et al. Epidemiology of IPF in Italy. ERS Annual Congress, Monaco, Settembre 2014.Google Scholar
  20. 20.
    Harari S, Caminati A, Albera C, et al. Efficacy of pirfenidone for idiopathic pulmonary fibrosis: an Italian real life study. Respir Med. 2015;109(7):904–13.  https://doi.org/10.1016/j.rmed.2015.04.010.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61:980–5.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Maesano IA, Nunes H, et al. Epidemiology of idiopathic pulmonary fibrosis in Europe—an update. Sarcoidosis. 2013;30:6–12.Google Scholar
  23. 23.
    Thomeer MJ, et al. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J. 2001;18(Suppl 32):114s–8s.Google Scholar
  24. 24.
    Lopez-Campos JL, Rodriguez-Becerra E. Incidence of interstitial lung diseases in the south of Spain 1998-2000: the RENIA study. Eur J Epidemiol. 2004;19:155–61.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Hutchinson JP, et al. Increasing global mortality from Idiopathic Pulmonary Fibrosis in the 21st century. Ann Am Thorac Soc. 2014;11(8):1176–85.PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Vyshedskiy A, et al. Mechanism of inspiratory and expiratory crackles. Chest. 2009;135:156–64.PubMedCrossRefPubMedCentralGoogle Scholar
  27. 27.
    Schulze K. Management of idiopathic pulmonary fibrosis and pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis. 2013;30S:33–6.Google Scholar
  28. 28.
    Cerveri I, Rossi A. Manuale di fisiopatologia respiratoria. Milano-Pisa: AIPO Ricerche Edizioni—Pacini Editore; 2015.Google Scholar
  29. 29.
    Agustí AG, Roca J, Gea J, et al. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1991;143:219–25.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Grenier P, Valeyre D, Cluzel P, et al. Chronic diffuse interstitial lung disease: diagnostic value of chest radiography and high-resolution CT. Radiology. 1991;179:123–32.PubMedCrossRefGoogle Scholar
  31. 31.
    Sverzellati N, Wells AU, Tomassetti S, et al. Biopsy-proved idiopathic pulmonary fibrosis: spectrum of nondiagnostic thin-section CT diagnoses. Radiology. 2010;254:957–64.PubMedCrossRefGoogle Scholar
  32. 32.
    Hunninghake GW, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;164:193–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Poletti V, Ravaglia C, Buccioli M. Idiopathic pulmonary fibrosis: diagnosis and prognostic evaluation. Respiration. 2013;86:5–12.PubMedCrossRefGoogle Scholar
  34. 34.
    Spagnolo P, Tonelli R, Cocconelli E, et al. Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. Multidiscip Respir Med. 2012;7:42.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;9:1004–14.CrossRefGoogle Scholar
  36. 36.
    Ohshimo S, Bonella F, Cui A, et al. Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179:1043–7.PubMedCrossRefGoogle Scholar
  37. 37.
    Spagnolo P, Luppi F, Rossi G, Richeldi L. To BAL or not to BAL. Is this a problem in diagnosing IPF? Am J Respir Crit Care Med. 2009;15:379–80.CrossRefGoogle Scholar
  38. 38.
    Pesci A, Ricchiuti R, Ruggiero R, De Micheli A. Bronchoalveolar lavage in idiopathic pulmonary fibrosis. What does it tell us? Respir Med. 2010;104:S70–3.PubMedCrossRefGoogle Scholar
  39. 39.
    Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014;307(9):681–91.CrossRefGoogle Scholar
  40. 40.
    King TE Jr, Albera C, Bradford WZ, et al. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am J Respir Crit Care Med. 2014;189:825–31.PubMedCrossRefGoogle Scholar
  41. 41.
    Noble PW, Albera C, et al. CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis: two randomised trials. Lancet. 2011;377:1760–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Richeldi L, du Bois RM, Raghu G, et al. INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2071–82.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Caminati A, Cassandro R, Torre O, et al. Severe idiopathic pulmonary fibrosis: what can be done? Eur Respir Rev. 2017;26:170047.PubMedCrossRefGoogle Scholar
  44. 44.
    Luppi F, Cerri S, Beghè B, et al. Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis. Respir Med. 2004;98:1035–44.PubMedCrossRefGoogle Scholar
  45. 45.
    Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–77.PubMedCrossRefGoogle Scholar
  46. 46.
    Kistler KD, Nalysnyk L, Rotella P, et al. Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med. 2014;14:139.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the pulmonary transplantation council of the international society for heart and lung transplantation. J Heart Lung Transplant. 2015;34(1):1–15.PubMedCrossRefGoogle Scholar
  48. 48.
    Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37:356–63.CrossRefGoogle Scholar
  49. 49.
    Ryerson CJ, Cottin V, et al. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J. 2015;46:512–20.PubMedCrossRefGoogle Scholar
  50. 50.
    Akira M, Kozuka T, Yamamoto S, et al. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178:372–8.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Juarez MM, Chan AL, Norris GL, et al. Acute exacerbation of idiopathic pulmonary fibrosis—a review of current and novel pharmacotherapies. J Thorac Dis. 2015;7(3):499–519.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Bajwah S, Higginson IJ, Ross JR, et al. The palliative care needs for fibrotic interstitial lung disease: a qualitative study of patients informal caregivers and health professionals. Palliat Med. 2013;27:869–76.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Cure palliative dei pazienti con patologie respiratorie croniche avanzate non oncologiche. Position paper della Associazione Italiana Pneumologi Ospedalieri (AIPO) Documento approvato dal Consiglio Direttivo S.I.A.A.R.T.I. Todi, 5 marzo 2011.Google Scholar
  54. 54.
    WHO definition of palliative care. http://www.who.int/cancer/palliative/definition/en/. Accessed 1 June 2017.
  55. 55.
    Lindell KO, Kavalieratos D, et al. The palliative care needs of patients with idiopathic pulmonary fibrosis: a qualitative study of patients and family caregivers. Heart Lung. 2017;46:24–9.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Kreuter M, Bendstrup E, Russell AM, Bajwah S, Lindell K, et al. Palliative care in interstitial lung disease: living well. Lancet Respir Med. 2017;5(12):968–80.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Bell EC, Cox NS, Goh N, et al. Oxygen therapy for interstitial lung disease: a systematic review. Eur Respir Rev. 2017;26:160080.PubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Santosa PS, Cravoa J, Esquinas AM. New perspectives for the use of high-flow nasal oxygen. Rev Port Pneumol. 2016;22(6):368.Google Scholar
  59. 59.
    Rayner L, et al. The management of depression in palliative care: draft European clinical guidelines. London: King’s College London; 2009.Google Scholar
  60. 60.
    Gifford HA. Noninvasive ventilation as a palliative measure. Curr Opin Support Palliat Care. 2014;8(3):218–24.PubMedCrossRefPubMedCentralGoogle Scholar
  61. 61.
    Rush B, Wiskar K, Berger L, Griesdale D. The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: a nationwide retrospective cohort analysis. Respir Med. 2016;111:72–6.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • M. Del Donno
    • 1
  • A. Di Sorbo
    • 1
  • A. Micco
    • 1
  1. 1.U.O.C. di Pneumologia - A.O. “G. Rummo”BeneventoItaly

Personalised recommendations